AXLRx Eli Lilly intelligence — Neurology: 1 report covering Neurology.
Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
We use analytics cookies to see how visitors use AXLRx. They're only set if you accept — decline and none are placed. See our Privacy Policy.